Frederick L Glick Net Worth

The estimated Net Worth of Frederick L Glick is at least $3.26 Thousand dollars as of 23 March 2020. Frederick Glick owns over 5,000 units of Sonnet BioTherapeutics Inc stock worth over $3,261 and over the last 6 years Frederick sold SONN stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Frederick Glick SONN stock SEC Form 4 insiders trading

Frederick has made over 3 trades of the Sonnet BioTherapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Frederick bought 5,000 units of SONN stock worth $2,550 on 23 March 2020.

The largest trade Frederick's ever made was buying 11,764 units of Sonnet BioTherapeutics Inc stock on 1 December 2018 worth over $20,705. On average, Frederick trades about 5,191 units every 119 days since 2018. As of 23 March 2020 Frederick still owns at least 4,000 units of Sonnet BioTherapeutics Inc stock.

You can see the complete history of Frederick Glick stock trades at the bottom of the page.

What's Frederick Glick's mailing address?

Frederick's mailing address filed with the SEC is 7621 LITTLE AVENUE, SUITE 414, , CHARLOTTE, NC, 28226.

Insiders trading at Sonnet BioTherapeutics Inc

Over the last 7 years, insiders at Sonnet BioTherapeutics Inc have traded over $53,380 worth of Sonnet BioTherapeutics Inc stock and bought 641,484 units worth $290,512 . The most active insiders traders include Pankaj Mohan, Donald J. Griffith, and Michael D Pruitt. On average, Sonnet BioTherapeutics Inc executives and independent directors trade stock every 86 days with the average trade being worth of $21,474. The most recent stock trade was executed by Raghu Rao on 27 October 2023, trading 15,625 units of SONN stock currently worth $12,739.

What does Sonnet BioTherapeutics Inc do?

sonnet biotherapeutics is an early stage company developing a pipeline of bifunctional therapies that attack immune-modulating targets to control cancer cells. sonnet biotherapeutics is utilizing a platform approach to develop a library of cancer-fighting immunotherapies. sonnet is based in cranbury, new jersey. sonnet mission: sonnet biotherapeutics is a platform enabled proof-of-concept engine created to generate immuno-oncology candidates and develop them into phase ii assets. we are leveraging a unique ip driven platform: ● single chain platform with pk enhancement ● selectively targeting tumors and their micro-environment ● validated targets only ● dual targeting can create synergies

Complete history of Frederick Glick stock trades at Sonnet BioTherapeutics Inc

Sonnet BioTherapeutics Inc executives and stock owners

Sonnet BioTherapeutics Inc executives and other stock owners filed with the SEC include:

• Dr. Pankaj Mohan Ph.D.,
  Founder, Chairman. CEO & Pres
• Dr. Pankaj Mohan,
  Founder, Chairman. CEO & Pres
• Jay Cross,
  Chief Financial Officer
• Dr. John K. Cini Ph.D.,
  Chief Scientific Officer & Co-Founder
• Dr. Richard T. Kenney FACP, M.D.,
  Chief Medical Officer
• Manuel Dafonseca,
  Head of Clinical Operations
• Dr. Richard T. Kenney,
  Chief Medical Officer
• Susan Dexter,
  Chief Technical Officer
• Frederick L Glick,
  President
• Albert D. Dyrness,
  Director
• Lori Mc Neill,
  Director
• Gregory Evan Kraut,
  Director
• Larry Spitcaufsky,
  
• Richard Adams,
  
• Neil G Kiefer,
  Director
• Russell Jacob Page,
  Director
• Keith J Johnson,
  Director
• Troy Matson Shadoin,
  Chief Accounting Officer
• Patrick Clay Harkleroad,
  Chief Financial Officer
• Michael D Pruitt,
  CEO, Chairman
• J Eric Wagoner,
  Director
• John K. Cini,
  Chief Scientific Officer
• Donald J. Griffith,
  Director
• Susan Dexter,
  Chief Technical Officer
• John Harry Iii Cross,
  Chief Financial Officer
• Nailesh Bhatt,
  Director
• Pankaj Mohan,
  Chairman, President and CEO
• Terence Anthony Rugg,
  Chief Medical Officer
• Raghu Rao,
  Director
• Richard T Kenney,
  Chief Medical Officer